PEG-modified/site-mutated IL-2 SHR-1916

A polyethylene glycol (PEG)-modified and site-mutated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, PEG-modified/site-mutated IL-2 SHR-1916 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the selective proliferation of CD8+ T cells and natural killer (NK) cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.